New reproductive assay from Siemens Healthineers
The Anti-Müllerian Hormone Assay reveals a patient's ovarian reserve information
15 May 2024
Siemens Healthineers now offers the Anti-Müllerian Hormone (AMH) Assay to quickly evaluate ovarian reserve. The AMH Assay is an important addition to a laboratory's reproductive endocrinology test menu as it aids a physician's initial assessment about initiating in vitro fertilization (IVF) with a patient. Physicians use AMH test results, which indicate the volume of remaining eggs, to determine whether a patient's ovaries may respond favorably to IVF.
IVF is the most common form of assisted reproductive technology, and it is costly, time-consuming, and invasive. The insight the AMH provides can help doctors better understand a patient's ovarian reserve and assist in consulting patients about whether to undergo IVF with a view to likelihood of success. Once in treatment, data gained from AMH testing can help reduce the number of IVF attempts, which can reduce financial cost as well as minimize adverse reactions associated with treatment.
“Planning for pregnancy is very personal, and when planning for pregnancy does become top-of-mind, the reality is that naturally occurring fertility changes can create barriers to conception and require support through IVF,” said Sharon Bracken, head of Diagnostics, Siemens Healthineers. “Since IVF success is directly linked to ovarian reserve, AMH test results can help doctors empower patients as they work toward the complex decision about whether to pursue or continue IVF.”